1. Home
  2. ZLAB vs DOGZ Comparison

ZLAB vs DOGZ Comparison

Compare ZLAB & DOGZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ZLAB
  • DOGZ
  • Stock Information
  • Founded
  • ZLAB 2013
  • DOGZ 2003
  • Country
  • ZLAB Cayman Islands
  • DOGZ China
  • Employees
  • ZLAB N/A
  • DOGZ N/A
  • Industry
  • ZLAB Biotechnology: Pharmaceutical Preparations
  • DOGZ Miscellaneous manufacturing industries
  • Sector
  • ZLAB Health Care
  • DOGZ Consumer Discretionary
  • Exchange
  • ZLAB Nasdaq
  • DOGZ Nasdaq
  • Market Cap
  • ZLAB 3.5B
  • DOGZ N/A
  • IPO Year
  • ZLAB 2017
  • DOGZ 2017
  • Fundamental
  • Price
  • ZLAB $32.00
  • DOGZ $17.53
  • Analyst Decision
  • ZLAB Buy
  • DOGZ
  • Analyst Count
  • ZLAB 4
  • DOGZ 0
  • Target Price
  • ZLAB $47.37
  • DOGZ N/A
  • AVG Volume (30 Days)
  • ZLAB 1.7M
  • DOGZ 93.6K
  • Earning Date
  • ZLAB 05-08-2025
  • DOGZ 05-16-2025
  • Dividend Yield
  • ZLAB N/A
  • DOGZ N/A
  • EPS Growth
  • ZLAB N/A
  • DOGZ N/A
  • EPS
  • ZLAB N/A
  • DOGZ N/A
  • Revenue
  • ZLAB $398,988,000.00
  • DOGZ $20,258,926.00
  • Revenue This Year
  • ZLAB $45.57
  • DOGZ N/A
  • Revenue Next Year
  • ZLAB $47.91
  • DOGZ N/A
  • P/E Ratio
  • ZLAB N/A
  • DOGZ N/A
  • Revenue Growth
  • ZLAB 49.59
  • DOGZ 46.16
  • 52 Week Low
  • ZLAB $15.65
  • DOGZ $5.40
  • 52 Week High
  • ZLAB $39.77
  • DOGZ $58.50
  • Technical
  • Relative Strength Index (RSI)
  • ZLAB 49.83
  • DOGZ 32.86
  • Support Level
  • ZLAB $28.34
  • DOGZ $15.00
  • Resistance Level
  • ZLAB $34.59
  • DOGZ $18.29
  • Average True Range (ATR)
  • ZLAB 2.12
  • DOGZ 2.77
  • MACD
  • ZLAB 0.40
  • DOGZ -0.42
  • Stochastic Oscillator
  • ZLAB 74.98
  • DOGZ 17.57

About ZLAB Zai Lab Limited

Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-1218 (CCR8) Solid Tumors, ZL-1310 (DLL3 ADC) ES-SCLC Other NECs, ZL-6301 (ROR1 ADC) Solid Tumors, ZL 6201 (LRRC15 ADC) Solid Tumors.

Share on Social Networks: